Table 1
| SWOG/ Support |
STUDY | R E G |
O P E N |
ARM | ACCR. GOAL |
TOTAL REGS. |
REGS. LAST 12 Month |
REGS. LAST 6 Month |
REGS. LAST 3 Month |
REGS. LAST 30 DAYS |
REGS. LAST 7 DAYS |
DATE OF FIRST REG. |
# of ACT. INSTs |
# of CURR IRBs |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SWOG | S1320-Adv, BRAF mut, Inter v Contin | 1 | Y | 1 Lead-in Continuous Dosing | 280 | 224 | 49 | 12 | 5 | 3 | 0 | 09/19/2014 | 225 | 99 |
| 224 | 49 | 12 | 5 | 3 | 0 | |||||||||
| 2 | Y | 2 Continuous Dosing | 237 | 95 | 23 | 9 | 3 | 1 | 0 | 09/19/2014 | ||||
| 3 Intermittent Dosing | 90 | 19 | 7 | 1 | 0 | 0 | ||||||||
| 185 | 42 | 16 | 4 | 1 | 0 | |||||||||
| S1512-Melan, Adv, Desmoplastic, MK-3475 (pembro) | 1 | Y | 1 MK-3475 (pembrolizumab) | 77 | 17 | 14 | 10 | 5 | 3 | 1 | 02/06/2017 | 90 | 42 | |
| 17 | 14 | 10 | 5 | 3 | 1 | |||||||||
| S1607-MELAN, Adv, T-VEC, MK-3475 | 1 | Y | 1 T-VEC + MK-3475(pembrolizumab) | 64 | 5 | 5 | 5 | 3 | 3 | 1 | 06/05/2018 | 30 | 18 | |
| 5 | 5 | 5 | 3 | 3 | 1 | |||||||||
| S1616-MELAN, Adv, Ipilimumab ± Nivolumab | 1 | Y | 1 Ipilimumab | 94 | 8 | 8 | 6 | 1 | 0 | 0 | 10/23/2017 | 233 | 94 | |
| 2 Nivolumab + Ipilimumab | 16 | 16 | 10 | 4 | 1 | 1 | ||||||||
| 24 | 24 | 16 | 5 | 1 | 1 | |||||||||
| Yes | EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T | 1 | E | Total Registrations | 30 | 8 | 4 | 4 | 0 | 0 | 11/03/2015 | 349 | 141 | |
| 30 | 8 | 4 | 4 | 0 | 0 | |||||||||
| 2 | E | Total Registrations | 12 | 7 | 5 | 5 | 1 | 0 | 11/03/2015 | |||||
| 12 | 7 | 5 | 5 | 1 | 0 | |||||||||
| EA6141-Melan, Avd, Nivolumab+Ipi ± Sargmostim | 1 | E | Total Registrations | 36 | 0 | 0 | 0 | 0 | 0 | 03/25/2016 | 314 | 134 | ||
| 36 | 0 | 0 | 0 | 0 | 0 | |||||||||